Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental Neurology2075-54732409-2533Research Center of Neurology31310.17816/psaic313UnknownThe course of the acute period of ischemic stroke after inravenous thrombolysisDomashenkoM. A.mdomashenko@gmail.comMaksimovaMarina Yu.mdomashenko@gmail.comhttps://orcid.org/0000-0002-7682-6672LoskutnikovM. A.mdomashenko@gmail.comNikonovAlexey A.<p>Cand. Sci. (Med.), neurologist, 2<sup>nd</sup> Neurological department, Institute of Clinical and Preventive Neurology</p>mdomashenko@gmail.comhttps://orcid.org/0000-0003-4934-1423BryukhovV. V.mdomashenko@gmail.comResearch Center of NeurologyResearch Center of Neurology, Moscow1303201151525703022017Copyright © 2011, Domashenko M.A., Maksimova M.Y., Loskutnikov M.A., Nikonov A.A., Bryukhov V.V.2011<div class="entry-content">
<p>Intravenous (i.v.) thrombolytic therapy of acute ischemic strokeis highly effective in selected group of patients. The most commoncomplications of systemic thrombolysis are intracerebralhaematomas, allergic reactions and acute hypotension. Theearly reocclusion/rethrombosis of intracranial arteries also mayinfluency the efficacy of thrombolysis. The clinical cases ofallergic reactions, acute hypotension and early reocclusion inthe first 24 hours after i.v. thrombolysis are described in the article.It is concluded that monitoring of neurological status andhaemodynamic parameters during and 24 hours after i.v. thrombolysisare the important factors of good outcome.</p>
</div>
<div class="clear"></div>
<div class="entry-meta"></div>thrombolysisischemic strokecomplicationsтромболизисишемический инсультосложнения[Пирадов М.А. Интенсивная терапия инсульта: взгляд на проблему. Анналы клинической и экспериментальной неврологии 2007; 1: 17–22.][Adams H. et al. Guidelines for the management of adults with ischemic stroke. Stroke 2007; 38: 1655–1711.][Ahmed N. et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITSISTR. Lancet Neurology 2010; 9: 866–874.][Alexandrov A.V., Grotta J.C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002, 59 (6): 862–867.][Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008. http://www.eso-stroke.org/recommendations][Lansberg M.G. et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007; 38: 2275–2278.][Wardlaw C., Wardlaw J. Therapeutic thrombolysis for acute ischaemic stroke. BMJ, 2003 (1); 326 (7383): 233–234.]